Hutchinson-Gilford Progeria Syndrome (HGPS)

🧬 Hutchinson-Gilford Progeria Syndrome (HGPS), often called progeria, is a very rare genetic disorder causing features of premature ageing in childhood. It is usually caused by a de novo mutation in the LMNA gene, most commonly producing an abnormal lamin A protein called progerin.

⚙️ Lamin A is important for maintaining the structure of the nuclear envelope. In HGPS, progerin accumulates in cells, disrupting nuclear stability, gene expression, DNA repair, and vascular smooth muscle function. This explains why the most serious complications are cardiovascular rather than cognitive.

Clinical Features

• 👶 Normal appearance at birth, with features developing in infancy or early childhood
• 📉 Severe growth failure and low body weight
• 👴 Characteristic facial appearance: prominent eyes, thin nose, small jaw, and scalp vein prominence
• 💇 Hair loss, including scalp hair, eyebrows, and eyelashes
• 🦴 Joint stiffness, reduced mobility, hip problems, and osteolysis
• 🦷 Delayed tooth eruption and dental crowding
• 🧴 Thin, tight, or scleroderma-like skin
• ❤️ Early-onset atherosclerosis, which is the major cause of morbidity and mortality

Important Clinical Point

🧠 Intelligence and neurodevelopment are usually normal. This is important when counselling families, because the condition primarily affects growth, skin, bones, dentition, and the cardiovascular system rather than cognition.

Diagnosis

• 🔍 Suspect HGPS in a child with postnatal growth failure, alopecia, characteristic facial features, skin changes, and joint stiffness.
• 🧬 Confirm diagnosis with genetic testing for LMNA mutation.
• ❤️ Baseline and ongoing cardiovascular assessment is essential, as vascular disease may progress silently.

Complications

• ❤️ Accelerated atherosclerosis
• 🧠 Stroke or transient ischaemic attacks
• 💔 Myocardial infarction
• 🦴 Hip dislocation, joint contractures, and skeletal fragility
• 👂 Hearing impairment
• 🦷 Dental crowding and delayed dentition

Management

🏥 Management should be multidisciplinary and usually involves paediatrics, clinical genetics, cardiology, physiotherapy, occupational therapy, dietetics, dentistry, audiology, psychology, and specialist rare disease services.

• ❤️ Regular cardiovascular monitoring, including blood pressure, vascular imaging, ECG, and echocardiography where appropriate
• 🍽️ Nutritional support with high-calorie intake and frequent meals
• 🦴 Physiotherapy and occupational therapy to preserve mobility and function
• 🦷 Dental surveillance and management of crowding or delayed tooth eruption
• 👂 Hearing assessment and support if needed
• 💬 Psychological and family support
• 🧬 Genetic counselling for the family, although most cases are new mutations

Targeted Treatment

💊 Lonafarnib is a farnesyltransferase inhibitor used as targeted treatment for genetically confirmed HGPS and some related progeroid laminopathies. It reduces farnesylation of progerin, helping to reduce its harmful attachment to the nuclear membrane.

📈 Lonafarnib is not a cure, but studies show it can improve survival and cardiovascular measures. Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhoea, so specialist monitoring is needed.

Prognosis

⚠️ HGPS is life-limiting, mainly because of premature cardiovascular disease. Death most commonly results from myocardial infarction or stroke. Early recognition, cardiovascular surveillance, supportive care, and access to specialist treatment can improve quality of life and may improve survival.

Key Learning Points

• 🧬 HGPS is usually due to a de novo LMNA mutation causing abnormal progerin production.
• 👶 Children often appear normal at birth but develop growth failure and premature ageing features in early childhood.
• 🧠 Cognition is usually normal.
• ❤️ Cardiovascular disease is the major cause of morbidity and mortality.
• 💊 Lonafarnib is a targeted therapy but is not curative.